These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 21083517

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data.
    Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, Maykut R, Peachey G.
    Respir Med; 2010 Sep; 104(9):1381-5. PubMed ID: 20599369
    [Abstract] [Full Text] [Related]

  • 6. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany.
    Korn S, Thielen A, Seyfried S, Taube C, Kornmann O, Buhl R.
    Respir Med; 2009 Nov; 103(11):1725-31. PubMed ID: 19515548
    [Abstract] [Full Text] [Related]

  • 7. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma.
    Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S.
    Curr Med Res Opin; 2011 Jan; 27(1):163-9. PubMed ID: 21121874
    [Abstract] [Full Text] [Related]

  • 8. Use of omalizumab in a severe asthma clinic.
    Gibson PG, Taramarcaz P, McDonald VM.
    Respirology; 2007 Nov; 12 Suppl 3():S35-44; discussion S45-7. PubMed ID: 17956518
    [Abstract] [Full Text] [Related]

  • 9. Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.
    Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.
    J Biol Regul Homeost Agents; 2011 Nov; 25(2):177-86. PubMed ID: 21880206
    [Abstract] [Full Text] [Related]

  • 10. Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis.
    Busse WW, Massanari M, Kianifard F, Geba GP.
    Curr Med Res Opin; 2007 Oct; 23(10):2379-86. PubMed ID: 17711616
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Omalizumab in the treatment of severe asthma: efficacy and current problems.
    Pelaia G, Renda T, Romeo P, Busceti MT, Maselli R.
    Ther Adv Respir Dis; 2008 Dec; 2(6):409-21. PubMed ID: 19124386
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of omalizumab in non-allergic severe asthma.
    Domingo C, Pomares X, Angril N, Rudi N, Amengual MJ, Mirapeix RM.
    J Biol Regul Homeost Agents; 2013 Dec; 27(1):45-53. PubMed ID: 23489686
    [Abstract] [Full Text] [Related]

  • 16. One year treatment with omalizumab is effective and well tolerated in Japanese Patients with moderate-to-severe persistent asthma.
    Ohta K, Yamamoto M, Sato N, Ikeda K, Miyamoto T.
    Allergol Int; 2010 Jun; 59(2):167-74. PubMed ID: 20179417
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness of omalizumab in reducing corticosteroid burden in patients with moderate to severe persistent allergic asthma.
    Karpel J, Massanari M, Geba GP, Kianifard F, Inhaber N, Zeldin RK.
    Ann Allergy Asthma Immunol; 2010 Dec; 105(6):465-70. PubMed ID: 21130385
    [Abstract] [Full Text] [Related]

  • 19. [Omalizumab, an anti-IgE monoclonal antibody to treat severe asthma].
    Michils A, Sternon J.
    J Pharm Belg; 2006 Dec; 61(3):83-7. PubMed ID: 17058881
    [Abstract] [Full Text] [Related]

  • 20. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M, Tonnel AB.
    Rev Mal Respir; 2005 Dec; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.